Clinical Trial Search

Primary: Time to Meeting Discharge Criteria (TMDC) — 4.03; 4.00 days — p=0.633

Primary: Mean 7-day Angioedema Activity Score (AAS7) — 2.8; 1.6; 0.69; 0.20 score on a scale

Primary: Time to Beginning of Relief of Symptoms — 62; 508; 61 minutes — p=0.003

Primary: Time to Beginning of Relief of Symptoms — 68; 122; 258; 62.5 minutes — p=0.001

Primary: Time to Start of Relief of Symptoms From HAE Attack (Intent to Treat (ITT) Subject Population) — 0.46 hours

Primary: Time to Start of Relief of Symptoms From HAE Attack — 1.17; 0.5; 1.5 Hours — p=0.0025

Primary: The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and…

Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm

Primary: (PAI-1) Plasminogen Activator Inhibitor -1 Antigen — 4.59; 3.78; 13.59; 17.8 ng/ml — p=0.03

Primary: HAE Attacks/Week — 0.9; 0.4 attacks/week

Primary: Median Dose Required to Increase the Systolic Blood Pressure (SBP) — 35; 43; 45 ng/kg/min

Primary: Composite of the Maximum Sequential Organ Failure Assessment (SOFA) Score and Death Within 30 Days — 0; 1 score on a scale

Primary: Number of Participants With Interoperative Hypotension — 76; 95 Participants — p=0.03

Primary: The Time-normalized Number of Hereditary Angioedema Attacks — 0.04; 0.02; 0.12; 0.13 attacks/day — p=< 0.001

Primary: Time to Beginning of Relief of Symptoms — 90; 152 minutes

Primary: Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment — -14.83; -13.10; -14.37; 1.92 Score on a scale — p=<…

Primary: Number of Confirmed HAE Attacks — 0.519; 0.527; 0.249; 0.852 HAE attacks per week — p=<0.001

Primary: Person-time Incidence Rates (Subject Based) — 0.01; 0.03; 0.00; 0.01 participants with events/year

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 7 Participants

Primary: Time to Onset of Symptom Relief (TOSR) — 2.5; 4.6 Hours — p=0.142

Primary: Modeled C1-esterase Inhibitor Functional Activity Trough Level — 30.3; 45.9; 80.6 percent functional activity

Primary: Weight-for-age Z-score at 14 Months of Age — -0.62; -0.42 standard deviation — p=0.28

Primary: Frequency of Side Effects (=Systemic Reaction, SR) During Venom Immunotherapy (VIT) — 19; 74 Participants — p=0.25

Primary: Number of HAE Attacks — 2.74; 4.36; 7.18 attacks

Primary: Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat — 1.4; 1.8; 1.9; 1.9 l/min/m2 — p=0.09

Primary: Time to Beginning of Substantial Relief of the Defining Symptom — 2.0; 4.0 hours — p=0.048

Primary: Hierarchical Composite Endpoint — 81; 73 score on a scale (range 1 to 152)

Primary: Safety & Tolerability — 94; 240; 58; 119 Participants

Primary: Time-Normalized Number of Attacks (NNA) for Participants During a Treatment Period — 1.611; 3.931 Number of attacks — p=<0.0001

Primary: Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Treatment Period — 1.967; 0.480; 0.526; 0.257 Attacks per 4 weeks — p=<0.001